FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144920286> ?p ?o ?g. }

• W2144920286 endingPage "1092" @default.
• W2144920286 startingPage "1083" @default.
• W2144920286 abstract "Background. The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials. Methods. We conducted an open-label, randomized study to compare the noninferiority of ddI/3TC/EFV with the lamivudine-zidovudine tablet and EFV (COM/EFV), both administered with food to improve tolerability and convenience. Patients were stratified by HIV-1 RNA level of <5.0 log10 or ⩾5.0 log10 copies/mL. The primary end point was the percentage of patients with an HIV-1 RNA level of <50 copies/mL at week 48, determined by intention-to-treat analysis. Results. Three hundred sixty-nine patients were randomized: 186 for ddI/3TC/EFV treatment and 183 for COM/EFV treatment. Both groups were well matched in terms of baseline characteristics; 19.3% of patients received a Centers for Disease Control and Prevention assessment of clinical category C, median HIV RNA level was 5.0 log10 copies/mL, and median CD4+ cell count was 208 cells/µL. At week 48, by intention-to-treat analysis, 70% of patients in the ddI/3TC/EFV group and 63% of patients in the COM/EFV group had an HIV-1 RNA level of <50 copies/mL (treatment difference, 7.1%; 95% confidence interval, −2.39% to 16.59%). Fourteen patients (8%) in the COM/EFV arm and 26 patients (14%) in the ddI/3TC/EFV arm discontinued the study medication because of adverse events (P=.046). One patient (1%) in the ddI/3TC/EFV arm and 11 patients (6%) in the COM/EFV arm discontinued medication because of hematological toxicity (P=.003). Conclusions. At week 48, ddI/3TC/EFV administered once per day with food did not have results inferior to those of COM/EFV treatment. A statistically significantly higher proportion of patients in the COM/EFV arm than in the ddI/3TC/EFV arm discontinued therapy because of adverse events, mainly because of hematological toxicity. Clinical trials registration. NCT00256828." @default.
• W2144920286 created "2016-06-24" @default.
• W2144920286 creator A5001003748 @default.
• W2144920286 creator A5004497510 @default.
• W2144920286 creator A5005014573 @default.
• W2144920286 creator A5017751675 @default.
• W2144920286 creator A5023915997 @default.
• W2144920286 creator A5024965105 @default.
• W2144920286 creator A5025610151 @default.
• W2144920286 creator A5026298718 @default.
• W2144920286 creator A5034126710 @default.
• W2144920286 creator A5037679984 @default.
• W2144920286 creator A5042618056 @default.
• W2144920286 creator A5045367981 @default.
• W2144920286 creator A5055227485 @default.
• W2144920286 creator A5072944678 @default.
• W2144920286 date "2008-10-15" @default.
• W2144920286 modified "2023-10-07" @default.
• W2144920286 title "Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903" @default.
• W2144920286 cites W1501037119 @default.
• W2144920286 cites W1992249780 @default.
• W2144920286 cites W2005873387 @default.
• W2144920286 cites W2015796602 @default.
• W2144920286 cites W2021877795 @default.
• W2144920286 cites W2024438075 @default.
• W2144920286 cites W2030633257 @default.
• W2144920286 cites W2037757078 @default.
• W2144920286 cites W2043427266 @default.
• W2144920286 cites W2049886213 @default.
• W2144920286 cites W2052332986 @default.
• W2144920286 cites W2079948480 @default.
• W2144920286 cites W2092672275 @default.
• W2144920286 cites W2096494132 @default.
• W2144920286 cites W2110937893 @default.
• W2144920286 cites W2120711252 @default.
• W2144920286 cites W2122280827 @default.
• W2144920286 cites W2407521229 @default.
• W2144920286 cites W27272420 @default.
• W2144920286 cites W4242649823 @default.
• W2144920286 doi "https://doi.org/10.1086/592114" @default.
• W2144920286 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18781872" @default.
• W2144920286 hasPublicationYear "2008" @default.
• W2144920286 type Work @default.
• W2144920286 sameAs 2144920286 @default.
• W2144920286 citedByCount "34" @default.
• W2144920286 countsByYear W21449202862012 @default.
• W2144920286 countsByYear W21449202862013 @default.
• W2144920286 countsByYear W21449202862014 @default.
• W2144920286 countsByYear W21449202862015 @default.
• W2144920286 countsByYear W21449202862016 @default.
• W2144920286 countsByYear W21449202862017 @default.
• W2144920286 countsByYear W21449202862018 @default.
• W2144920286 countsByYear W21449202862019 @default.
• W2144920286 crossrefType "journal-article" @default.
• W2144920286 hasAuthorship W2144920286A5001003748 @default.
• W2144920286 hasAuthorship W2144920286A5004497510 @default.
• W2144920286 hasAuthorship W2144920286A5005014573 @default.
• W2144920286 hasAuthorship W2144920286A5017751675 @default.
• W2144920286 hasAuthorship W2144920286A5023915997 @default.
• W2144920286 hasAuthorship W2144920286A5024965105 @default.
• W2144920286 hasAuthorship W2144920286A5025610151 @default.
• W2144920286 hasAuthorship W2144920286A5026298718 @default.
• W2144920286 hasAuthorship W2144920286A5034126710 @default.
• W2144920286 hasAuthorship W2144920286A5037679984 @default.
• W2144920286 hasAuthorship W2144920286A5042618056 @default.
• W2144920286 hasAuthorship W2144920286A5045367981 @default.
• W2144920286 hasAuthorship W2144920286A5055227485 @default.
• W2144920286 hasAuthorship W2144920286A5072944678 @default.
• W2144920286 hasBestOaLocation W21449202861 @default.
• W2144920286 hasConcept C126322002 @default.
• W2144920286 hasConcept C142462285 @default.
• W2144920286 hasConcept C159047783 @default.
• W2144920286 hasConcept C168563851 @default.
• W2144920286 hasConcept C197934379 @default.
• W2144920286 hasConcept C2522874641 @default.
• W2144920286 hasConcept C2777447569 @default.
• W2144920286 hasConcept C2777869810 @default.
• W2144920286 hasConcept C2778375690 @default.
• W2144920286 hasConcept C2779889181 @default.
• W2144920286 hasConcept C2780216070 @default.
• W2144920286 hasConcept C2780593183 @default.
• W2144920286 hasConcept C2780727368 @default.
• W2144920286 hasConcept C2781432083 @default.
• W2144920286 hasConcept C2993143319 @default.
• W2144920286 hasConcept C3013748606 @default.
• W2144920286 hasConcept C535046627 @default.
• W2144920286 hasConcept C71924100 @default.
• W2144920286 hasConcept C90924648 @default.
• W2144920286 hasConceptScore W2144920286C126322002 @default.
• W2144920286 hasConceptScore W2144920286C142462285 @default.
• W2144920286 hasConceptScore W2144920286C159047783 @default.
• W2144920286 hasConceptScore W2144920286C168563851 @default.
• W2144920286 hasConceptScore W2144920286C197934379 @default.
• W2144920286 hasConceptScore W2144920286C2522874641 @default.
• W2144920286 hasConceptScore W2144920286C2777447569 @default.
• W2144920286 hasConceptScore W2144920286C2777869810 @default.
• W2144920286 hasConceptScore W2144920286C2778375690 @default.
• W2144920286 hasConceptScore W2144920286C2779889181 @default.

• next